Abrdn Healthcare Investors (HQH)

16,86 +0,30 (+1,81%) In data: 10:05AM EDT. Mercato aperto.

Abrdn Healthcare Investors

1900 Market Street
Suite 200
Philadelphia, PA 19103
United States
215 405 5700

Settore/i: Financial Services
Settore: Asset Management
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Daniel R. Omstead M.S, Ph.D.	Portfolio Manager	N/D	N/D	1953
Dr. Jason C. Akus M.B.A., M.D., MBA	Vice President of Research and Portfolio Manager	N/D	N/D	N/D
Mr. Christopher F. Brinzey MBA	Senior Vice President of Research and Portfolio Manager	N/D	N/D	N/D
Dr. Frank T. Gentile Ph.D.	Senior Vice President of Research and Portfolio Manager	N/D	N/D	1962

Gli importi risalgono al giorno 31 dicembre 2013 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Abrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. Abrdn Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States.

Governance aziendale

L'ISS Governance QualityScore di Abrdn Healthcare Investors al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.